Definitive Contract 75N93019C00008
Award Date
5/31/19
Potential Completion Date
2/28/21
Potential Value
$299K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
PAI Life Sciences Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Seattle, WA 98102, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $599,999 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Parabon NanoLabs, Inc., a small business. The objective of the contract is to develop a DNA-based HIV vaccine that will stimulate production of broadly neutralizing antibodies against the HIV-1 envelope protein trimer antigen. This is a Phase I Small Business Innovation Research (SBIR) contract under the...
This $441,905 firm fixed-price definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, to PAI Life Sciences Inc. for the development of a prophylactic onchocerciasis (river blindness) vaccine. The contract is designated as a total small business set-aside. PAI Life Sciences, a small disadvantaged business, will collaborate with Thomas Jefferson University and New York Blood...
This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small...
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to PAI Life Sciences Inc., a self-certified small disadvantaged business. The $2,338,680.13 definitive contract is for the Phase II development of a prophylactic onchocerciasis (river blindness) vaccine under the SBIR program. The contract is a cost plus fixed fee arrangement with a completion date of May 15, 2024. PAI Life Sciences is collaborating with Thomas...
This $299,040 firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to design and synthesize a new PLGA-based nanoparticle with an optimal protein-adjuvant formulation that combines targeting and controlled delivery for immunization...
This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...
This is a $444,428 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to PAI Life Sciences Inc., a self-certified small disadvantaged business. The contract is for the development of a Leishmania vaccine, combining parasite and vector components. This contract was designated as a total small business set-aside. PAI Life Sciences has a history of securing federal contracts and grants, particularly from NIAID, for the development of vaccines and...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Neovaxsyn Inc., a minority-owned small disadvantaged business located in Ames, Iowa. The $300,000 firm-fixed-price contract supports the development of innovative HIV/AIDS vaccine technologies, including the use of nanoparticle delivery systems and strategies to induce broadly...
This federal contract award to Neovaxsyn Inc., a minority-owned small disadvantaged business, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services. The $300,000 firm fixed-price contract supports the development of a next-generation immunoprevention platform against HIV-1, with a final completion date of October 31, 2025. The contract was awarded under the Small Business Innovation Research (SBIR) program, which...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded PAI Life Sciences Inc. a $597,953 definitive contract to develop late stage adjuvant mimics based on toll-like receptor 4 agonists. As a self-certified small disadvantaged business, this contract was designated as a total small business set aside. PAI Life Sciences will provide products and services to the National Institute of Allergy and Infectious Diseases in support of their program for late stage...